| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0272-6386(99)70035-1 |
| P698 | PubMed publication ID | 10561134 |
| P50 | author | Ivan Rychlík | Q61138620 |
| P2093 | author name string | Locatelli F | |
| Ritz E | |||
| Halimi S | |||
| Rychlík I | |||
| P2860 | cites work | Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study | Q74464563 |
| Some trends in chronic renal replacement therapy in Australia and New Zealand, 1997 | Q74502415 | ||
| Evolution of renal replacement therapy in Central and Eastern Europe 7 years after political and economical liberation. Central and Eastern Europe Advisory Board in Chronic Renal Failure | Q74502418 | ||
| A man with diabetes and unexplained renal failure | Q77347405 | ||
| Nephropathy in type II diabetes--epidemiological issues as viewed from Japan | Q77602608 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| Latin American Registry of dialysis and renal transplantation: 1993 annual dialysis data report | Q32144990 | ||
| Diabetic patients on renal replacement therapy: analysis of Catalan Registry data. Renal Registry Committee | Q32145017 | ||
| Nephropathy in type 2 diabetes | Q33542374 | ||
| Prevention of diabetic renal disease with special reference to microalbuminuria | Q40415958 | ||
| The rising tide of endstage renal failure from diabetic nephropathy type II--an epidemiological analysis. | Q40453312 | ||
| Annual Report of the German Renal Registry 1998. QuaSi-Niere Task Group for Quality Assurance in Renal Replacement Therapy | Q40812157 | ||
| Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects | Q40870460 | ||
| Renal transplantation in patients with type 2 diabetes mellitus | Q40950706 | ||
| Diabetic nephropathy in type II diabetes | Q41003506 | ||
| End-stage renal disease in China | Q41082550 | ||
| Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction | Q42758399 | ||
| Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients | Q43829155 | ||
| A rapid rise in the number of type-2 diabetics in kidney failure. Not just a problem of nephrologists | Q44108191 | ||
| Pathogenesis, prevention, and treatment of diabetic nephropathy | Q47770839 | ||
| Renal disease and hypertension in non-insulin-dependent diabetes mellitus. | Q50539640 | ||
| Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetic patients in Europe. | Q50605243 | ||
| Nephrology and renal replacement therapy in Romania. | Q50621782 | ||
| Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. | Q50650486 | ||
| Epidemiology of end-stage renal failure in Reunion Island (results from the registry of the Indian Ocean Society of Nephrology). | Q50882985 | ||
| The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. | Q51597336 | ||
| How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. | Q52891704 | ||
| Transcribing diabetes | Q60086645 | ||
| Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients | Q68028517 | ||
| Similar risks of nephropathy in patients with type I or type II diabetes mellitus | Q69268410 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis | Q70520152 | ||
| Physical activity and employment status of patients on maintenance dialysis | Q71410025 | ||
| The diabetic patient with ESRD: how to select the modality of renal replacement | Q71653279 | ||
| Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency | Q72066129 | ||
| Community diabetes care. A 10-year perspective | Q72408212 | ||
| Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetes mellitus. The case of mainland France and of overseas French territories | Q72616649 | ||
| Survival and predictors of death in dialysed diabetic patients | Q72616654 | ||
| Recommendations for reducing the high morbidity and mortality of United States maintenance dialysis patients. The National Kidney Foundation | Q72870269 | ||
| The kidney in mitochondrial cytopathies | Q73182916 | ||
| Current status of renal replacement therapy in Japan: results of the annual survey of the Japanese Society for Dialysis Therapy | Q73397158 | ||
| There is room for improvement of preterminal care in diabetic patients with end-stage renal failure--the epidemiological evidence in Germany | Q73569339 | ||
| P433 | issue | 5 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 795-808 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions | |
| P478 | volume | 34 |
| Q42512729 | 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells |
| Q44418726 | A Low-Iron-Available, Polyphenol-Enriched, Carbohydrate-Restricted Diet to Slow Progression of Diabetic Nephropathy |
| Q42861202 | A Study of Inflammatory Status in Nephropathy Patients with History of Type-II Diabetes Mellitus Undergoing Haemodialysis |
| Q35211693 | A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition |
| Q46979928 | A simplified Cockcroft-Gault formula to improve the prediction of the glomerular filtration rate in diabetic patients |
| Q63440925 | ACACβ gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes |
| Q37601128 | AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy |
| Q58612380 | Aberrant DNA methylation of Tgfb1 in diabetic kidney mesangial cells |
| Q51739062 | Acetylshikonin from Zicao ameliorates renal dysfunction and fibrosis in diabetic mice by inhibiting TGF-β1/Smad pathway. |
| Q92362766 | Adaptive Method for Quantitative Estimation of Glucose and Fructose Concentrations in Aqueous Solutions Based on Infrared Nanoantenna Optics |
| Q35688028 | Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. |
| Q81166769 | Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats |
| Q33862368 | All-Cause Mortality Risk in Australian Women with Impaired Fasting Glucose and Diabetes |
| Q37236273 | Allelic depletion of grem1 attenuates diabetic kidney disease |
| Q33608656 | Altered retinoic acid metabolism in diabetic mouse kidney identified by O isotopic labeling and 2D mass spectrometry |
| Q40866836 | An angiotensin II type 1 receptor blocker prevents renal injury via inhibition of the Notch pathway in Ins2 Akita diabetic mice |
| Q50546677 | Analysis of proportional mean residual life model with latent variables. |
| Q36659505 | Anemia and diabetic nephropathy |
| Q34075013 | Angiogenesis and chronic kidney disease |
| Q35054987 | Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes. |
| Q43423190 | Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis |
| Q53087421 | Association between genetic polymorphism of the angiotensin-converting enzyme and diabetic nephropathy: a meta-analysis comprising 26,580 subjects. |
| Q91676304 | Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. Statistical Regression Modeling to P |
| Q37166283 | Association of Serum Adropin Concentrations with Diabetic Nephropathy. |
| Q33622283 | Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus |
| Q64990398 | Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. |
| Q37700360 | Augmenting podocyte injury promotes advanced diabetic kidney disease in Akita mice. |
| Q36470970 | Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer |
| Q34377103 | Biochemistry and clinical role of human cystatin C. |
| Q53740601 | Biomarker for early renal microvascular and diabetic kidney diseases. |
| Q42705734 | Bisphenol-A induces podocytopathy with proteinuria in mice |
| Q45232179 | Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice |
| Q35071275 | Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy |
| Q91656692 | Blood pressure and phosphate level in diabetic and non-diabetic kidney disease: Results of the cross-sectional "Low Clearance Consultation" study |
| Q49226476 | CAPE-pNO2 ameliorated diabetic nephropathy through regulating the Akt/NF-κB/ iNOS pathway in STZ-induced diabetic mice. |
| Q35017214 | Calcitriol plays a protective role in diabetic nephropathy through anti-inflammatory effects |
| Q55509901 | Cardiovascular Risk Factors Accelerate Kidney Function Decline in Post−Myocardial Infarction Patients: The Alpha Omega Cohort Study. |
| Q34600815 | Cardiovascular abnormalities and hypertension in the elderly dialysis patient |
| Q41514778 | Cardiovascular complications of type 2 diabetes in youth |
| Q35538153 | Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors |
| Q46038265 | Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. |
| Q35470865 | Chaperonin-containing t-complex protein-1 subunit β as a possible biomarker for the phase of glomerular hyperfiltration of diabetic nephropathy |
| Q46152671 | Characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions |
| Q37476055 | Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy |
| Q35857721 | Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin |
| Q51136081 | Chronic bilateral renal denervation attenuates renal injury in a transgenic rat model of diabetic nephropathy. |
| Q60683706 | Chronic renal failure in North Central Province of Sri Lanka: an environmentally induced disease |
| Q61804334 | Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis |
| Q43029526 | Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis |
| Q37976425 | Clinical predictors of non-diabetic renal disease and role of renal biopsy in diabetic patients with renal involvement: a single centre review. |
| Q36924964 | Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase |
| Q37439729 | Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice |
| Q36699386 | Comprehensive analysis of the mouse renal cortex using two-dimensional HPLC - tandem mass spectrometry |
| Q36448309 | Contrast-induced nephrotoxicity: clinical landscape |
| Q38939078 | Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology. |
| Q51035312 | Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). |
| Q39172851 | Correlation between Microalbuminuria and Hypertension in Type 2 Diabetic Patients |
| Q33357230 | Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy |
| Q46979934 | Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes |
| Q34056044 | Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model |
| Q42970293 | Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy |
| Q27023025 | Diabetes and end-stage renal disease; a review article on new concepts |
| Q36035797 | Diabetes and hypertension: pathogenesis, prevention and treatment |
| Q38109814 | Diabetes and its comorbidities--where East meets West |
| Q33583012 | Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease |
| Q28086840 | Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets |
| Q36084248 | Diabetic Nephropathy Induced by Increased Ace Gene Dosage Is Associated with High Renal Levels of Angiotensin (1-7) and Bradykinin |
| Q36114211 | Diabetic Retinopathy in Patients with Diabetic Nephropathy: Development and Progression. |
| Q44664522 | Diabetic complications. Micro and macroangiopathic end-organ damage |
| Q92501574 | Diabetic kidney disease: A systematic review on the role of epigenetics as diagnostic and prognostic marker |
| Q27021392 | Diabetic kidney disease: from physiology to therapeutics |
| Q28742785 | Diabetic nephropathy - Epidemiology in Asia and the current state of treatment |
| Q26996008 | Diabetic nephropathy and extracellular matrix |
| Q36589609 | Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis |
| Q36210022 | Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran |
| Q92266624 | Differential Expression of Urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in Individuals with Diabetic Kidney Disease |
| Q36790432 | Differential expression of genes associated with the progression of renal disease in the kidneys of liver-specific glucokinase gene knockout mice. |
| Q28580099 | Differential expression of type IV collagen isoforms in rat glomerular endothelial and mesangial cells |
| Q38070781 | Direct renin inhibition in chronic kidney disease |
| Q80166842 | Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone? |
| Q41854872 | Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. |
| Q79794049 | Early referral to a nephrologist is associated with better outcomes in type 2 diabetes patients with end-stage renal disease |
| Q35591301 | Early-onset diabetic E1-DN mice develop albuminuria and glomerular injury typical of diabetic nephropathy. |
| Q24236347 | Education programmes for people with diabetic kidney disease |
| Q24241653 | Education programmes for people with diabetic kidney disease |
| Q34336244 | Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy |
| Q34787799 | Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial |
| Q57298171 | Effect of personalized moderate exercise training on Wistar rats fed with a fructose enriched water |
| Q38208950 | Effects of GLP-1 in the kidney |
| Q33612248 | Effects of Low-Molecular-Weight Fucoidan and High Stability Fucoxanthin on Glucose Homeostasis, Lipid Metabolism, and Liver Function in a Mouse Model of Type II Diabetes |
| Q41776334 | Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study |
| Q64231698 | Efficacy and Safety of Safflower Yellow in Early Diabetic Nephropathy: A Meta-Analysis |
| Q36362830 | Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis |
| Q51934249 | End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. |
| Q42909119 | Epigenetic changes and alteration of Fbn1 and Col3A1 gene expression under hyperglycaemic and hyperinsulinaemic conditions |
| Q37576010 | Establishment of an inflamed animal model of diabetic nephropathy |
| Q37235275 | Evaluating Pharmacological Effects of Two Major Components of Shuangdan Oral Liquid: Role of Danshensu and Paeonol in Diabetic Nephropathy Rat |
| Q37120730 | Evaluating the Effect of Knowledge, Attitude, and Practice on Self-Management in Type 2 Diabetic Patients on Dialysis |
| Q48078314 | Exercise training improves aerobic capacity, muscle strength, and quality of life in renal transplant recipients |
| Q36961321 | Exosomes from high glucose-treated glomerular endothelial cells activate mesangial cells to promote renal fibrosis |
| Q83586600 | Expression of cholecystokinin-1 receptor is correlated with proteinuria in human diabetic nephropathy |
| Q35059565 | Factors affecting the progression of diabetic nephropathy and its complications: a single-center experience in Saudi Arabia |
| Q44548255 | Factors affecting the progression of renal dysfunction and the importance of salt restriction in patients with type 2 diabetic kidney disease |
| Q37260211 | Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury |
| Q33300811 | Genome-wide association with diabetes-related traits in the Framingham Heart Study |
| Q36802038 | Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in france: a cross-sectional study. |
| Q92964183 | Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study |
| Q33436604 | Grape seed powder improves renal failure of chronic kidney disease patients |
| Q54979361 | Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study. |
| Q34994649 | H(2)S inhibits hyperglycemia-induced intrarenal renin-angiotensin system activation via attenuation of reactive oxygen species generation |
| Q79610876 | Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis |
| Q46713029 | Hemodialysis in patients older than 65 years with end-stage renal failure--comparison of outcome in patients with and without diabetes |
| Q24235372 | Heparin and related substances for preventing diabetic kidney disease |
| Q24245107 | Heparin and related substances for preventing diabetic kidney disease |
| Q40435852 | High ambient glucose is effect neutral on cell death and proliferation in human proximal tubular epithelial cells |
| Q43363527 | How well are hypertension and albuminuria treated in type II diabetic patients? |
| Q51429794 | Hyperoside ameliorates glomerulosclerosis in diabetic nephropathy by downregulating miR-21. |
| Q36604947 | Hypertension and antihypertensive treatment of diabetic nephropathy |
| Q40113463 | Hypertensive patients with and without kidney disease: assessment of risk factors |
| Q36831657 | Hypothesis--haptoglobin genotype and diabetic nephropathy |
| Q34731321 | Identifying parameters to distinguish non-diabetic renal diseases from diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis |
| Q79387620 | Impact of diabetes on haemoglobin levels in renal disease |
| Q37709163 | Impact of diabetes-related gene polymorphisms on the clinical characteristics of type 2 diabetes Chinese Han population |
| Q44869305 | Impact of initial blood pressure on the mortality of diabetics undergoing renal replacement therapy |
| Q104473910 | Impact of type 2 diabetes mellitus on kidney transplant rates and clinical outcomes among waitlisted candidates in a single center European experience |
| Q44690129 | Increase in prevalence of diabetes mellitus as a cause of dialytic end-stage renal disease: analysis of 20 years in the west region of Paraná |
| Q38427732 | Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-term glycaemic control |
| Q51869814 | Induction of hyperglycemia in adult intrauterine growth-restricted rats: effects on renal function. |
| Q36659502 | Inflammation and diabetic nephropathy |
| Q34023543 | Inflammation in diabetic kidney disease |
| Q89658327 | Inflammatory Targets in Diabetic Nephropathy |
| Q35133177 | Inflammatory cytokines in diabetic nephropathy. |
| Q47799102 | Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus |
| Q38756737 | Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease. |
| Q33401681 | Inter-practice variation in diagnosing hypertension and diabetes mellitus: a cross-sectional study in general practice |
| Q57415213 | Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM) |
| Q36530849 | Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice |
| Q37216559 | Irbesartan: a review of its use in hypertension and diabetic nephropathy |
| Q35752881 | Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy |
| Q44978900 | Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes? |
| Q52685042 | JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. |
| Q36477666 | Lack of association between anemia and renal disease progression in Chinese patients with type 2 diabetes |
| Q41788971 | Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. |
| Q38065316 | Leptin therapy in type 2 diabetes |
| Q36783886 | Limitations and future treatment options in type 2 diabetes with renal impairment |
| Q43497625 | Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus |
| Q38438433 | Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. |
| Q47136824 | Long-term Follow-up for Type 2 Diabetes Mellitus after Gastrectomy in Non-morbidly Obese Patients with Gastric Cancer: the Legitimacy of Onco-metabolic Surgery |
| Q58794490 | Low linolenic and linoleic acid consumption are associated with chronic kidney disease in patients with type 2 diabetes |
| Q39254993 | Low-Protein Diets in Diabetic Chronic Kidney Disease (CKD) Patients: Are They Feasible and Worth the Effort? |
| Q35612623 | Low-protein vegetarian diet with alpha-chetoanalogues prior to pre-emptive pancreas-kidney transplantation |
| Q73107216 | Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France--2001) |
| Q45008126 | Management of patients on the waiting list for deceased donor kidney transplantation |
| Q54098275 | Mechanism of hypertension in diabetic nephropathy. |
| Q39801451 | Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy. |
| Q43699416 | Multicenter study of the renal transplantation selection process: multivariate analysis |
| Q27008887 | N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes |
| Q34024321 | N-glycosylation of carnosinase influences protein secretion and enzyme activity: implications for hyperglycemia |
| Q92129314 | Natural Hydrogen Sulfide Donors from Allium sp. as a Nutraceutical Approach in Type 2 Diabetes Prevention and Therapy |
| Q51055207 | Non-diabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome. |
| Q34443235 | Novel approaches to the treatment of progressive renal disease |
| Q26862757 | Novel role of parathyroid hormone-related protein in the pathophysiology of the diabetic kidney: evidence from experimental and human diabetic nephropathy |
| Q36345732 | Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells |
| Q37003803 | Oxidative stress in diabetic nephropathy |
| Q33560342 | Paeoniflorin prevents diabetic nephropathy in rats |
| Q54576285 | Parathyroid hormone-related protein is a hypertrophy factor for human mesangial cells: Implications for diabetic nephropathy. |
| Q50433834 | Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. |
| Q35673446 | Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy |
| Q64095815 | Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons |
| Q24203643 | Pentoxifylline for diabetic kidney disease |
| Q24243734 | Pentoxifylline for diabetic kidney disease |
| Q35976372 | Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies |
| Q34515483 | Pharmacotherapy of hypertension in patients with diabetes mellitus |
| Q43286010 | Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. |
| Q45769086 | Postischemic inflammatory syndrome: a critical mechanism of progression in diabetic nephropathy. |
| Q37403557 | Predictors of diabetic retinopathy in patients with type 2 diabetes who have normoalbuminuria |
| Q57301414 | Preliminary clinical assessment and non- toxicity evaluation of an ayurvedic formulation BGR-34 in NIDDM |
| Q89849960 | Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China: A Meta-Analysis of Observational Studies |
| Q41187589 | Prevalence of macro- and microvascular complications in patients with type 2 diabetes and kidney disease with or without albuminuria in a single Chinese Diabetes Centre |
| Q33899286 | Prevalence of microalbuminuria and risk factor analysis in type 2 diabetes patients in Albania: the need for accurate and early diagnosis of diabetic nephropathy |
| Q36648858 | Preventing microalbuminuria in patients with type 2 diabetes |
| Q28195746 | Prevention and Treatment of Diabetic Nephropathy in Older Patients |
| Q42398743 | Preventive and Protective Effect of Nishamalaki in STZ Induced Diabetic Complications in Wistar Rats |
| Q46790709 | Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study |
| Q37314981 | Profile of chronic renal failure in diabetes at initiation of hemodialysis in the nephrology and dialysis service of the military hospital in Rabat, Morocco |
| Q34444873 | Profile of diabetic in chronic hemodialysis: a multicenter study in Morocco |
| Q51333859 | Prolonged elevated postprandial sugar augments severity in kidney disease: a north Indian hospital-based study. |
| Q35553269 | Prospective trials on anemia of chronic disease: The Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) |
| Q39051958 | Quality of care of patients with type 2 diabetes in a Tunisian university hospital |
| Q28270272 | RAGE and CYBA polymorphisms are associated with microalbuminuria and end-stage renal disease onset in a cohort of type 1 diabetes mellitus patients over a 20-year follow-up |
| Q42263637 | RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy |
| Q36334589 | Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study |
| Q38204682 | Renal denervation--implications for chronic kidney disease |
| Q34215822 | Renal function and renal disease in the elderly: Part I. |
| Q35416245 | Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy |
| Q33359672 | Renal lesions in patients with type 2 diabetes: a puzzle waiting to be solved |
| Q36362572 | Renal protection in hypertensive patients: selection of antihypertensive therapy |
| Q34075168 | Renal protective potential of antihypertensive drugs |
| Q37738213 | Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension |
| Q51561666 | Renal transplantation from cadaveric donor after myocardial revascularization: still a matter of concern? |
| Q40209870 | Renal transplantation in Iran over the past two decades: a trend analysis. |
| Q54295290 | Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. |
| Q35125651 | Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats |
| Q34385405 | Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus |
| Q38054089 | Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications |
| Q52652372 | RhoA/rho kinase signaling reduces connexin43 expression in high glucose-treated glomerular mesangial cells with zonula occludens-1 involvement. |
| Q33183125 | Role of ACE inhibitors in patients with diabetes mellitus |
| Q26849691 | Role of T cells in type 2 diabetic nephropathy |
| Q47099497 | Saxagliptin Attenuates Albuminuria by Inhibiting Podocyte Epithelial- to-Mesenchymal Transition via SDF-1α in Diabetic Nephropathy |
| Q37982112 | Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment |
| Q33801070 | Screening for Chronic Kidney Disease in Adult Males in Vojvodina: A Cross-sectional Study |
| Q46818521 | Secondary contributors to bone loss in osteoporosis related hip fractures |
| Q36586227 | Selecting indicators for the quality of diabetes care at the health systems level in OECD countries |
| Q87168028 | Serum 25-hydroxyvitamin D level and diabetic nephropathy in patients with type 2 diabetes mellitus |
| Q45818886 | Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway |
| Q64259863 | Sprout Extract Protect Renal Mesangial Cell Dysfunction against High Glucose by Modulating AMPK and NADPH Oxidase Signaling |
| Q39888257 | Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid |
| Q33697462 | Study of Neutrophil-lymphocyte Ratio as Novel Marker for Diabetic Nephropathy in Type 2 Diabetes |
| Q34606527 | Suppression of XBP1S mediates high glucose-induced oxidative stress and extracellular matrix synthesis in renal mesangial cell and kidney of diabetic rats |
| Q73397409 | Surgical alternatives to central venous catheters in chronic renal replacement therapy |
| Q46854252 | Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition |
| Q73173518 | Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? |
| Q24188236 | Systemic nutritional interventions for treating foot ulcers in people with diabetes |
| Q36072276 | Testing for microalbuminuria and albuminuria in diabetes should be as important as checking blood pressure |
| Q37438415 | The Impact of Diabetes Mellitus on Vascular Biomarkers in Patients with End-Stage Renal Disease. |
| Q26774377 | The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review |
| Q38778655 | The Kidney and Periodontal Disease (KAPD) study: A pilot randomized controlled trial testing the effect of non-surgical periodontal therapy on chronic kidney disease |
| Q35208122 | The anaemia of silent diabetic nephropathy-prevalence, physiopathology, and management |
| Q55512530 | The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. |
| Q37078185 | The clinical characteristics of normoalbuminuric renal insufficiency in Korean type 2 diabetic patients: a possible early stage renal complication. |
| Q57701988 | The contribution of chronic kidney disease to the global burden of major noncommunicable diseases |
| Q41989543 | The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'-implications for pre-clinical research and drug testing |
| Q36920518 | The diabetes prevention program and its global implications |
| Q34996116 | The effect of chinese herbal medicine on albuminuria levels in patients with diabetic nephropathy: a systematic review and meta-analysis. |
| Q36501844 | The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in isfahan, iran |
| Q40265807 | The parathyroid hormone-related protein system and diabetic nephropathy outcome in streptozotocin-induced diabetes |
| Q33808925 | The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy |
| Q36958293 | The relationship between neutrophil-to-lymphocyte ratio and albuminuria in type 2 diabetic patients: a pilot study |
| Q43113872 | The role of diabetes mellitus and hypertension in chronic kidney disease |
| Q36326359 | The role of inflammation as a pathogenic factor in the development of renal disease in diabetes |
| Q40153047 | The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. |
| Q38845378 | Toxicology of freshwater cyanobacteria |
| Q36102963 | Transforming growth factor beta contributes to progressive diabetic nephropathy |
| Q47585220 | Transforming growth factor-β1 and phosphatases modulate COX-2 protein expression and TAU phosphorylation in cultured immortalized podocytes |
| Q35740688 | Type 2 diabetes affects hippocampus volume differentially in men and women. |
| Q35114539 | Ultrasonography in chronic renal failure |
| Q43504523 | Underdiagnosis of diabetes mellitus in chronic dialysis patients on the renal transplant waiting list |
| Q64257959 | Understanding Human Physiological Limitations and Societal Pressures in Favor of Overeating Helps to Avoid Obesity |
| Q28073342 | Update on the treatment of type 2 diabetes mellitus |
| Q38258271 | Updating the natural history of diabetic nephropathy |
| Q55112495 | Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. |
| Q86951470 | Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress |
| Q40305513 | Weight change and risk of hyperglycaemia in elderly women |
| Q79904726 | [Measuring microalbuminuria in patients with diabetes: plea for harmonization] |
| Q79314860 | [Therapy and prophylaxis of renal failure] |
| Q53438325 | [Vascular and parenchymal diseases of the kidney]. |
Search more.